Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080145 · ClinicalTrials.gov registry record · NA
RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders
A NA study of Child Development Disorders, Pervasive, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 124
- Enrollment target
- 3
- Study locations
NCT00080145 is a NA study of Child Development Disorders, Pervasive that has completed, run by Yale University. The registered enrollment target is 124 participants, above the 78-participant average among 4 other Child Development Disorders, Pervasive trials with a reported enrollment target (59% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT00080145, a NA study of Child Development Disorders, Pervasive, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
- 3
- Study locations
Study Summary
This 24-week study will compare the safety and effectiveness of medication treatment alone (risperidone or aripiprazole) to medication treatment in combination with a parent management training program.
Conditions Studied
Interventions
- DRUG Risperidone
- BEHAVIORAL Behavior Therapy
Study Locations (3)
Connecticut
- Yale University - New Haven
Indiana
- Indiana University - Indianapolis
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080145
The ClinicalTrials.gov registry entry for NCT00080145 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 78-participant average among 4 other Child Development Disorders, Pervasive trials with a reported enrollment target (59% higher). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Child Development Disorders, Pervasive appearing as the primary indexed condition, and to 2 interventions - of which Risperidone is the first listed.
NCT00080145 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Indiana, Ohio.
Frequently Asked Questions
What is clinical trial NCT00080145 about?
NCT00080145 is a clinical study titled "RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders". This 24-week study will compare the safety and effectiveness of medication treatment alone (risperidone or aripiprazole) to medication treatment in combination with a parent management training program.
What is the current status of trial NCT00080145?
This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2004-02. Estimated completion is 2007-09.
What conditions does trial NCT00080145 study?
This clinical trial studies the following conditions: Child Development Disorders, Pervasive.
What interventions are being tested in trial NCT00080145?
The interventions under investigation include: Risperidone (DRUG), Behavior Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00080145?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00080145 being conducted?
This trial has 3 study locations across Connecticut, Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Child Development Disorders, Pervasive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
RECRUITING
-
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
COMPLETED · Phase 1
-
Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)
COMPLETED · Phase 1
-
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.